This, in turn, could enhance the TNFR2 CAR NK cell functions by neutralizing TNFR2 on cancer cells, T-regs, MDSCs, and B-regs, as well as other immunosuppressive cells, and at the same time killing cells via cytotoxic mediators. When comparing CAR NK cells with CAR T cells, it is evident that the incidence of cytokine release syndrome (CRS) and neurotoxicity is significantly lower in CAR NK cells (Fig. 12C) [344]. This evidence concerns the gene TNFRSF1B and cancer.